Trabectedin shows activity in ATREUS trial in patients with sarcomatoid malignant mesothelioma

(Pharmamar) PharmaMar today announced data from the Phase 2 ATREUS study in patients with sarcomatoid/biphasic malignant pleural mesothelioma showing that 41.2 percent of patients treated with the anticancer drug trabectedin in second line were alive and free of progression at 12 weeks. The median progression-free survival in these 17 evaluated patients was 8.3 weeks. The study will be presented at the 2015 ASCO Annual Meeting.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news